BIOSHIELD DISPUTE UNDERSCORES PROBLEMS WITH DEFENSE PROGRAM

By now, millions of anthrax vaccine shots developed through cutting-edge genetic engineering were supposed to be filling a new national stockpile of biodefense drugs. Instead, five years after anthrax attacks left five dead, sickened 17 and panicked the country, the nearly $1 billion contract awarded by the U.S. Department of Health and Human Services to a tiny and struggling San Francisco Bay Area biotechnology company is plagued with misfortune and delays. Boston Globe (http://www.boston.com/news/local/connecticut/articles/2006/10/01/bioshield_dispute_underscores_problems_with_defense_program/)